Cover Image
Market Research Report

Behavioral Disorders Drug Development Pipeline Review, 2017

Published by GlobalData Product code 564937
Published Content info 113 Pages
Delivery time: 1-2 business days
Price
Back to Top
Behavioral Disorders Drug Development Pipeline Review, 2017
Published: September 14, 2017 Content info: 113 Pages
Description

Executive Summary:

Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child's sex, family history, fragile X syndrome, Tourette syndrome and epilepsy. There are a total of 41 products in development for this indication, by 34 companies and 4 academic institutions. Key companies operating in this pipeline space include Addex Therapeutics, Confluence Pharmaceuticals and Immuron.

Obsessive-compulsive disorder (OCD) is characterized by unreasonable thoughts and fears (obsessions) that lead to do repetitive behaviors (compulsions). Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again. There are a total of 8 products in development for this indication by 7 companies. Key companies operating in this pipeline space include Addex Therapeutics, Abbvie, Omeros and Phytecs.

Finally, attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination and inability to sustain attention on tasks or activities. There are a total of 58 products in development for this indication, by 41 companies and 5 academic institutions. Key companies operating in this pipeline space include NLS Pharma, Aevi Genomic Medicine, Shire and Highland Therapeutics.

Across all three of these indications, transporters and receptors of neurotransmitters such as dopamine, glutamine and serotonin, plus G protein-coupled receptors and ion channels, are the most common targets, closely reflecting the current treatment landscape of these diseases.

The report, "Behavioral Disorders Drug Development Pipeline Review, 2017" provides an overview of the behavioral disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for autism, obsessive-compulsive disorder and attention deficit hyperactivity disorder and features dormant and discontinued projects.

Scope:

  • Which companies are the most active within the pipeline for behavioral disorder therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of behavioral disorders?

Reasons to buy:

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Table of Contents
Product Code: GBIHC018IDB

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Behavioral Disorders Report Coverage
  • 2.2. Autism. Overview
  • 2.3. Obsessive-Compulsive Disorder. Overview
  • 2.4. Attention Deficit Hyperactivity Disorder (ADHD). Overview

3. Therapeutics Development

  • 3.1. Autism
  • 3.2. Obsessive-Compulsive Disorder
  • 3.3. Attention Deficit Hyperactivity Disorder (ADHD)

4. Therapeutics Assessment

  • 4.1. Autism
  • 4.2. Obsessive-Compulsive Disorder
  • 4.3. Attention Deficit Hyperactivity Disorder (ADHD)

5. Companies Involved in Therapeutics Development

  • 5.1. Autism
  • 5.2. Obsessive-Compulsive Disorder
  • 5.3. Attention Deficit Hyperactivity Disorder (ADHD)

6. Dormant Projects

  • 6.1. Autism
  • 6.2. Obsessive-Compulsive Disorder
  • 6.3. Attention Deficit Hyperactivity Disorder (ADHD)

7. Discontinued Products

  • 7.1. Autism
  • 7.2. Obsessive-Compulsive Disorder
  • 7.3. Attention Deficit Hyperactivity Disorder (ADHD)

8. Product Development Milestones

  • 8.1. Autism
  • 8.2. Obsessive-Compulsive Disorder
  • 8.3. Attention Deficit Hyperactivity Disorder (ADHD)

9. Appendix

  • 9.1. Methodology
  • 9.2. Coverage
  • 9.3. Secondary Research
  • 9.4. Primary Research
  • 9.5. Expert Panel Validation
  • 9.6. Contact Us
  • 9.7. Disclaimer

List of Tables

  • Table 1: Number of Products under Development for Autism
  • Table 2: Number of Products under Development by Companies, Autism
  • Table 3: Number of Products under Development by Universities/Institutes, Autism
  • Table 4: Products under Development by Companies, Autism
  • Table 5: Products under Development by Universities/Institutes, Autism
  • Table 6: Number of Products under Development for Obsessive-Compulsive Disorder
  • Table 7: Number of Products under Development by Companies, Obsessive-Compulsive Disorder
  • Table 8: Products under Development by Companies, Obsessive-Compulsive Disorder
  • Table 9: Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD)
  • Table 10: Number of Products under Development by Companies, Attention Deficit Hyperactivity Disorder (ADHD)
  • Table 11: Number of Products under Development by Universities/Institutes, Attention Deficit Hyperactivity Disorder (ADHD)
  • Table 12: Products under Development by Companies, Attention Deficit Hyperactivity Disorder (ADHD)
  • Table 13: Products under Development by Universities/Institutes, Attention Deficit Hyperactivity Disorder (ADHD)
  • Table 14: Number of Products by Stage and Target, Autism
  • Table 15: Number of Products by Stage and Mechanism of Action, Autism
  • Table 16: Number of Products by Stage and Route of Administration, Autism
  • Table 17: Number of Products by Stage and Molecule Type, Autism
  • Table 18: Number of Products by Stage and Target, Obsessive-Compulsive Disorder
  • Table 19: Number of Products by Stage and Mechanism of Action, Obsessive-Compulsive Disorder
  • Table 20: Number of Products by Stage and Route of Administration, Obsessive-Compulsive Disorder
  • Table 21: Number of Products by Stage and Molecule Type, Obsessive-Compulsive Disorder
  • Table 22: Number of Products by Stage and Target, Attention Deficit Hyperactivity Disorder (ADHD)
  • Table 23: Number of Products by Stage and Mechanism of Action, Attention Deficit Hyperactivity Disorder (ADHD)
  • Table 24: Number of Products by Stage and Route of Administration, Attention Deficit Hyperactivity Disorder (ADHD)
  • Table 25: Number of Products by Stage and Molecule Type, Attention Deficit Hyperactivity Disorder (ADHD)
  • Table 26: Autism - Pipeline by 4D Pharma PLC
  • Table 27: Autism - Pipeline by Addex Therapeutics Ltd
  • Table 28: Autism - Pipeline by Aequus Pharmaceuticals Inc
  • Table 29: Autism - Pipeline by Aevi Genomic Medicine Inc
  • Table 30: Autism - Pipeline by AgeneBio Inc
  • Table 31: Autism - Pipeline by Anima Biotech Ltd
  • Table 32: Autism - Pipeline by APeT Holding BV
  • Table 33: Autism - Pipeline by BioCrea GmbH
  • Table 34: Autism - Pipeline by BioHealthonomics Inc
  • Table 35: Autism - Pipeline by BrainStorm Cell Therapeutics Inc
  • Table 36: Autism - Pipeline by Confluence Pharmaceuticals LLC
  • Table 37: Autism - Pipeline by Coronis NeuroSciences Ltd
  • Table 38: Autism - Pipeline by Curemark LLC
  • Table 39: Autism - Pipeline by DRI Biosciences Corp
  • Table 40: Autism - Pipeline by F. Hoffmann-La Roche Ltd
  • Table 41: Autism - Pipeline by GW Pharmaceuticals Plc
  • Table 42: Autism - Pipeline by Heptares Therapeutics Ltd
  • Table 43: Autism - Pipeline by Immuron Ltd
  • Table 44: Autism - Pipeline by Intra-Cellular Therapies Inc
  • Table 45: Autism - Pipeline by Leading BioSciences Inc
  • Table 46: Autism - Pipeline by MedDay SA
  • Table 47: Autism - Pipeline by Omeros Corp
  • Table 48: Autism - Pipeline by OptiNose US Inc
  • Table 49: Autism - Pipeline by Ovensa Inc
  • Table 50: Autism - Pipeline by Q BioMed Inc
  • Table 51: Autism - Pipeline by Sumitomo Dainippon Pharma Co Ltd
  • Table 52: Obsessive-Compulsive Disorder - Pipeline by AbbVie Inc
  • Table 53: Obsessive-Compulsive Disorder - Pipeline by Addex Therapeutics Ltd
  • Table 54: Obsessive-Compulsive Disorder - Pipeline by Amorsa Therapeutics Inc
  • Table 55: Obsessive-Compulsive Disorder - Pipeline by Omeros Corp
  • Table 56: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by 4P-Pharma SAS
  • Table 57: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Aevi Genomic Medicine Inc
  • Table 58: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Alcobra Ltd
  • Table 59: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience Holdings Inc
  • Table 60: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by APeT Holding BV
  • Table 61: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BCWorld Pharm Co Ltd
  • Table 62: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BioHealthonomics Inc
  • Table 63: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Cingulate Therapeutics LLC
  • Table 64: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical Inc
  • Table 65: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark LLC
  • Table 66: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corp
  • Table 67: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Eli Lilly and Company
  • Table 68: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by H. Lundbeck A/S
  • Table 69: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Heptares Therapeutics Ltd
  • Table 70: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Highland Therapeutics Inc
  • Table 71: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm Inc
  • Table 72: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Luc Therapeutics Inc
  • Table 73: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Merck & Co Inc
  • Table 74: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neos Therapeutics Inc
  • Table 75: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NeuroDerm Ltd
  • Table 76: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Novartis AG
  • Table 77: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Noven Pharmaceuticals Inc
  • Table 78: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Otsuka Pharmaceutical Co Ltd
  • Table 79: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by P2D Bioscience
  • Table 80: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Reviva Pharmaceuticals Inc
  • Table 81: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shire Plc
  • Table 82: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by SK Biopharmaceuticals Co Ltd
  • Table 83: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Sunovion Pharmaceuticals Inc
  • Table 84: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Supernus Pharmaceuticals Inc
  • Table 85: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taisho Pharmaceutical Holdings Co Ltd
  • Table 86: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Tris Pharma Inc
  • Table 87: Autism - Dormant Projects
  • Table 88: Obsessive-Compulsive Disorder - Dormant Projects
  • Table 89: Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects
  • Table 90: Autism - Discontinued Products
  • Table 91: Obsessive-Compulsive Disorder - Discontinued Products
  • Table 92: Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products

List of Figures

  • Figure 1: Number of Products under Development for Autism
  • Figure 2: Number of Products under Development by Companies, Autism
  • Figure 3: Number of Products under Development by Universities/Institutes, Autism
  • Figure 4: Number of Products under Development for Obsessive-Compulsive Disorder
  • Figure 5: Number of Products under Development by Companies, Obsessive-Compulsive Disorder
  • Figure 6: Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD)
  • Figure 7: Number of Products under Development by Companies, Attention Deficit Hyperactivity Disorder (ADHD)
  • Figure 8: Number of Products under Development by Universities/Institutes, Attention Deficit Hyperactivity Disorder (ADHD)
  • Figure 9: Number of Products by Top 10 Targets, Autism
  • Figure 10: Number of Products by Stage and Top 10 Targets, Autism
  • Figure 11: Number of Products by Top 10 Mechanism of Actions, Autism
  • Figure 12: Number of Products by Stage and Top 10 Mechanism of Actions, Autism
  • Figure 13: Number of Products by Routes of Administration, Autism
  • Figure 14: Number of Products by Stage and Routes of Administration, Autism
  • Figure 15: Number of Products by Molecule Types, Autism
  • Figure 16: Number of Products by Stage and Molecule Types, Autism
  • Figure 17: Number of Products by Targets, Obsessive-Compulsive Disorder
  • Figure 18: Number of Products by Stage and Targets, Obsessive-Compulsive Disorder
  • Figure 19: Number of Products by Mechanism of Actions, Obsessive-Compulsive Disorder
  • Figure 20: Number of Products by Stage and Mechanism of Actions, Obsessive-Compulsive Disorder
  • Figure 21: Number of Products by Stage and Routes of Administration, Obsessive-Compulsive Disorder
  • Figure 22: Number of Products by Stage and Molecule Types, Obsessive-Compulsive Disorder
  • Figure 23: Number of Products by Top 10 Targets, Attention Deficit Hyperactivity Disorder (ADHD)
  • Figure 24: Number of Products by Stage and Top 10 Targets, Attention Deficit Hyperactivity Disorder (ADHD)
  • Figure 25: Number of Products by Top 10 Mechanism of Actions, Attention Deficit Hyperactivity Disorder (ADHD)
  • Figure 26: Number of Products by Stage and Top 10 Mechanism of Actions, Attention Deficit Hyperactivity Disorder (ADHD)
  • Figure 27: Number of Products by Routes of Administration, Attention Deficit Hyperactivity Disorder (ADHD)
  • Figure 28: Number of Products by Stage and Routes of Administration, Attention Deficit Hyperactivity Disorder (ADHD)
  • Figure 29: Number of Products by Molecule Types, Attention Deficit Hyperactivity Disorder (ADHD)
  • Figure 30: Number of Products by Stage and Molecule Types, Attention Deficit Hyperactivity Disorder (ADHD)
Back to Top